AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00409097
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00995007
Drug: ZD6474 (Vandetanib)
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
Trial: NCT00995007
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
Trial: NCT04659525
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Trial: NCT04659525
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
Trial: NCT04551950
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin was administered intravenously as per standard of care.
Trial: NCT04551950
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel was administered intravenously as per standard of care.
Trial: NCT01491217
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
Trial: NCT05208801
Drug: Percutaneous injection
RxNorm normalized name: TEA LEAF 0.1 g in 1 mL PERCUTANEOUS INJECTION, SOLUTION
DrugBank: Tea leaf (DB10580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
Trial: NCT05208801
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of morphine 400mcg
Trial: NCT04551950
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab was administrated as indicated for standard of care.
Trial: NCT04551950
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin was administered intravenously as per standard of care.
Trial: NCT02639520
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 sachet of 8 g of granules; one single dose on Day 1
Trial: NCT05208801
Drug: Morphine+Bupivacaine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of 5mg of 0.5% bupivacaine chloride
Trial: NCT02639520
Drug: Fosfomycin trometamol-placebo
RxNorm normalized name: trometamol
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 sachet of 8 g of granules; one single dose on Day 1
Trial: NCT03270332
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation of 270μg albuterol through a spacer
Trial: NCT02073734
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 8mg/IV
Trial: NCT02937558
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
Trial: NCT02451943
Drug: Olaratumab
RxNorm normalized name: Olaratumab
DrugBank: Olaratumab (DB06043)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IV
Trial: NCT04666454
Drug: Dipyridamole 200 mg
RxNorm normalized name: dipyridamole 200 MG
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg b.i.d
Trial: NCT04666454
Drug: Apixaban 5 mg Oral Tablet
RxNorm normalized name: apixaban 5 MG Oral Tablet
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5mg b.i.d
Trial: NCT02777489
Drug: Perindopril
RxNorm normalized name: Perindopril
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
Trial: NCT04018157
Drug: Ketamine and dexmedetomidine and propofol and 0.9%saline
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
Trial: NCT03770780
Drug: SAGE-718
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-718 in combination with Ketamine
Trial: NCT04134676
Drug: Conditioned Media
RxNorm normalized name: Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
DrugBank: Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media (DB15728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
Trial: NCT01180296
Drug: oral micronized progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
Trial: NCT00210730
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00035568
Drug: Glucovance (metformin HCl/glyburide)
RxNorm normalized name: glyburide / metformin hydrochloride Oral Tablet [Glucovance]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00035568
Drug: or Metformin HCl alone
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00035568
Drug: or Glyburide alone.
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00166439
Drug: Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles
Trial: NCT03401385
Drug: Datopotamab Deruxtecan (Dato-DXd)
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total anti-TROP2 antibody and MAAA-1181a
Trial: NCT03401385
Drug: Steroid Containing Mouthwash
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mouthwash containing a steroid ingredient administered in sub-study
Trial: NCT03482492
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol iv
Trial: NCT03482492
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol iv
Trial: NCT01327469
Drug: Albendazole, 2 x 400mg
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 2 x 400mg
Trial: NCT01327469
Drug: Albendazole 400mg
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 400mg
Trial: NCT01327469
Drug: Mebendazole 500mg
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole 500mg
Trial: NCT01327469
Drug: Mebendazole 2 x 500mg
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole 2 x 500mg
Trial: NCT01327469
Drug: Pyrantel-oxantel + mebendazole
RxNorm normalized name: oxantel
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrantel-oxantel + mebendazole
Trial: NCT02048085
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
Trial: NCT02048085
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
Trial: NCT00429572
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2 intravenously Daily for 5 Days
Trial: NCT00429572
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70 mg/m\^2 intravenously Daily for 2 Days
Trial: NCT01375361
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
Trial: NCT01009554
Drug: Sodium Fluoride Dentifrice
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush in usual manner, twice daily, with a sodium fluoride dentifrice
Trial: NCT01405937
Drug: vaniprevir
RxNorm normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
Trial: NCT01419717
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by subcutaneous injection every 4 weeks (Q4W)
Trial: NCT00388011
Drug: Intranasal Morphine (MNS075) 3.75 mg
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Morphine (MNS075) 3.75 mg
Trial: NCT00388011
Drug: Intravenous Morphine 7.5 mg
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Morphine 7.5 mg
Trial: NCT00388011
Drug: Intranasal morphine (MNS075) 7.5 mg
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal morphine (MNS075) 7.5 mg
Trial: NCT00388011
Drug: Intranasal morphine (MNS075) 15 mg
RxNorm normalized name: morphine 15 MG/ML
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal morphine (MNS075) 15 mg
Trial: NCT00388011
Drug: Intranasal morphine (MNS075) 30 mg
RxNorm normalized name: morphine sulfate 30 MG
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal morphine (MNS075) 30 mg
Trial: NCT00093795
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 IV every 21 days for 6 cycles
Trial: NCT00093795
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m2 IV every 14 days for 4 cycles
Trial: NCT00093795
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m2 IV every 14 days for 4 cycles
Trial: NCT01405937
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
Trial: NCT02939248
Drug: Crushed ticagrelor followed by morphine
RxNorm normalized name: Ticagrelor
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
Trial: NCT03700749
Drug: 10%povidone-iodine + non-coated suture
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventions:~10% povidone-iodine non-coated suture non-coated suture
Trial: NCT03700749
Drug: 10%povidone-iodine + coated suture
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventions:~10% povidone-iodine triclosan coated suture
Trial: NCT01692691
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine IV - Day 1
Trial: NCT01692691
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine IV- Day 2
Trial: NCT01692691
Drug: Neulasta
RxNorm normalized name: Neulasta
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neulasta SC - Day 3
Trial: NCT00606866
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg twice daily
Trial: NCT00606866
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib, 400 mg twice daily
Trial: NCT01306331
Drug: Amphora
RxNorm normalized name: camphora
DrugBank: Taiwanofungus camphoratus fruiting body (DB19272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
Trial: NCT03483415
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
Trial: NCT03483415
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
Trial: NCT02303028
Drug: Topotecan and Pazopanib
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
Trial: NCT04110119
Drug: diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)
RxNorm normalized name: thiocolchicoside
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages
Trial: NCT04374006
Drug: Dienogest
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
Trial: NCT04374006
Drug: Propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
Trial: NCT00680823
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
Trial: NCT03318939
Drug: Poziotinib
RxNorm normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~* Cohorts 1-3: 16 mg QD~* Cohort 4: 8 mg BID~* Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~* Cohorts 6 and 7: 8 mg BID
Trial: NCT02414724
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01590160
Drug: Ganetespib
RxNorm normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, Using dose from Phase I
Trial: NCT00003917
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02748070
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02748070
Drug: Flonase
RxNorm normalized name: Flonase
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02414724
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00375219
Drug: Omacetaxine mepesuccinate
RxNorm normalized name: Omacetaxine Mepesuccinate
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction:~1.25 mg/m\^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m\^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years.
Trial: NCT05408104
Drug: tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
Trial: NCT00620568
Drug: SLV-313 SR
RxNorm normalized name: SLV-334
DrugBank: SLV-334 (DB15356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained release tablets taken once daily for 14 days
Trial: NCT01750541
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01750541
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01211665
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In intravenous form (for a daily dose of 1 g/day on treatment days).
Trial: NCT02511704
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple dose nicotine
Trial: NCT02773368
Drug: insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
Trial: NCT02773368
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IGlar will be given subcutaneously ( s.c., under the skin) once daily.
Trial: NCT03312361
Drug: 15% oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will inhale 15% oxygen for 2 hours to see how it affects them.
Trial: NCT00223054
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: retrospective analyze of drug levels in comparison to polymorphism
Trial: NCT00223054
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
Trial: NCT00223054
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
Trial: NCT00223054
Drug: cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
Trial: NCT04565249
Drug: PLN-74809
RxNorm normalized name: PLN-74809
DrugBank: PLN-74809 (DB16515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLN-74809
Trial: NCT03120676
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.